336 related articles for article (PubMed ID: 15098021)
1. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes.
Harel M; Aharoni A; Gaidukov L; Brumshtein B; Khersonsky O; Meged R; Dvir H; Ravelli RB; McCarthy A; Toker L; Silman I; Sussman JL; Tawfik DS
Nat Struct Mol Biol; 2004 May; 11(5):412-9. PubMed ID: 15098021
[TBL] [Abstract][Full Text] [Related]
2. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase.
Khersonsky O; Tawfik DS
Biochemistry; 2005 Apr; 44(16):6371-82. PubMed ID: 15835926
[TBL] [Abstract][Full Text] [Related]
3. 3-D structure of serum paraoxonase 1 sheds light on its activity, stability, solubility and crystallizability.
Harel M; Brumshtein B; Meged R; Dvir H; Ravelli RB; McCarthy A; Toker L; Silman I; Sussman JL
Arh Hig Rada Toksikol; 2007 Sep; 58(3):347-53. PubMed ID: 17913690
[TBL] [Abstract][Full Text] [Related]
4. Directed evolution of serum paraoxonase PON3 by family shuffling and ancestor/consensus mutagenesis, and its biochemical characterization.
Khersonsky O; Rosenblat M; Toker L; Yacobson S; Hugenmatter A; Silman I; Sussman JL; Aviram M; Tawfik DS
Biochemistry; 2009 Jul; 48(28):6644-54. PubMed ID: 19492856
[TBL] [Abstract][Full Text] [Related]
5. Lactonases with organophosphatase activity: structural and evolutionary perspectives.
Draganov DI
Chem Biol Interact; 2010 Sep; 187(1-3):370-2. PubMed ID: 20122908
[TBL] [Abstract][Full Text] [Related]
6. Directed evolution of recombinant serum paraoxonase (PON) variants.
Aharoni A; Tawfik DS
Discov Med; 2004 Apr; 4(21):120-4. PubMed ID: 20705007
[TBL] [Abstract][Full Text] [Related]
7. Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization.
Aharoni A; Gaidukov L; Yagur S; Toker L; Silman I; Tawfik DS
Proc Natl Acad Sci U S A; 2004 Jan; 101(2):482-7. PubMed ID: 14695884
[TBL] [Abstract][Full Text] [Related]
8. Directed evolution of sulfotransferases and paraoxonases by ancestral libraries.
Alcolombri U; Elias M; Tawfik DS
J Mol Biol; 2011 Aug; 411(4):837-53. PubMed ID: 21723874
[TBL] [Abstract][Full Text] [Related]
9. Catalytic versatility and backups in enzyme active sites: the case of serum paraoxonase 1.
Ben-David M; Elias M; Filippi JJ; Duñach E; Silman I; Sussman JL; Tawfik DS
J Mol Biol; 2012 May; 418(3-4):181-96. PubMed ID: 22387469
[TBL] [Abstract][Full Text] [Related]
10. The Structure and Function of Paraoxonase-1 and Its Comparison to Paraoxonase-2 and -3.
Taler-Verčič A; Goličnik M; Bavec A
Molecules; 2020 Dec; 25(24):. PubMed ID: 33348669
[TBL] [Abstract][Full Text] [Related]
11. The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.
She ZG; Chen HZ; Yan Y; Li H; Liu DP
Antioxid Redox Signal; 2012 Mar; 16(6):597-632. PubMed ID: 21867409
[TBL] [Abstract][Full Text] [Related]
12. Human paraoxonase: a promising approach for pre-treatment and therapy of organophosphorus poisoning.
Rochu D; Chabrière E; Masson P
Toxicology; 2007 Apr; 233(1-3):47-59. PubMed ID: 17007987
[TBL] [Abstract][Full Text] [Related]
13. The evolutionary origins of detoxifying enzymes: the mammalian serum paraoxonases (PONs) relate to bacterial homoserine lactonases.
Bar-Rogovsky H; Hugenmatter A; Tawfik DS
J Biol Chem; 2013 Aug; 288(33):23914-27. PubMed ID: 23788644
[TBL] [Abstract][Full Text] [Related]
14. The paraoxonase gene family and atherosclerosis.
Ng CJ; Shih DM; Hama SY; Villa N; Navab M; Reddy ST
Free Radic Biol Med; 2005 Jan; 38(2):153-63. PubMed ID: 15607899
[TBL] [Abstract][Full Text] [Related]
15. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases.
Aviram M; Rosenblat M
Methods Mol Biol; 2008; 477():259-76. PubMed ID: 19082953
[TBL] [Abstract][Full Text] [Related]
16. Catalytic stimulation by restrained active-site floppiness--the case of high density lipoprotein-bound serum paraoxonase-1.
Ben-David M; Sussman JL; Maxwell CI; Szeler K; Kamerlin SCL; Tawfik DS
J Mol Biol; 2015 Mar; 427(6 Pt B):1359-1374. PubMed ID: 25644661
[TBL] [Abstract][Full Text] [Related]
17. In silico analyses of substrate interactions with human serum paraoxonase 1.
Hu X; Jiang X; Lenz DE; Cerasoli DM; Wallqvist A
Proteins; 2009 May; 75(2):486-98. PubMed ID: 18951406
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of paraoxonases: a brief review.
Draganov DI; La Du BN
Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):78-88. PubMed ID: 14579013
[TBL] [Abstract][Full Text] [Related]
19. Tandem purification of two HDL-associated partner proteins in human plasma, paraoxonase (PON1) and phosphate binding protein (HPBP) using hydroxyapatite chromatography.
Renault F; Chabrière E; Andrieu JP; Dublet B; Masson P; Rochu D
J Chromatogr B Analyt Technol Biomed Life Sci; 2006 May; 836(1-2):15-21. PubMed ID: 16595195
[TBL] [Abstract][Full Text] [Related]
20. Active Site Hydrophobicity and the Convergent Evolution of Paraoxonase Activity in Structurally Divergent Enzymes: The Case of Serum Paraoxonase 1.
Blaha-Nelson D; Krüger DM; Szeler K; Ben-David M; Kamerlin SC
J Am Chem Soc; 2017 Jan; 139(3):1155-1167. PubMed ID: 28026940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
